ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

AbbVie has acquired rights to bretisilocin, a novel psychedelic compound for major depressive disorder, from Gilgamesh Pharmaceuticals for up to $1.2 billion. This strategic acquisition bolsters AbbVie's early-stage neuroscience pipeline, following bretisilocin's promising Phase II data showing rapid and durable antidepressant effects. The deal underscores AbbVie's continued aggressive expansion in neuroscience, aiming for long-term growth despite recent pipeline setbacks, such as the failure of a key candidate from its Cerevel Therapeutics acquisition.

Analysis

AbbVie is strategically expanding its neuroscience pipeline through the acquisition of rights to bretisilocin, a novel Phase II psychedelic compound for Major Depressive Disorder (MDD), from Gilgamesh Pharmaceuticals in a deal valued at up to $1.2 billion. This move is supported by compelling early clinical data, where bretisilocin demonstrated a statistically significant 21.6-point reduction on the MADRS depression scale compared to a 12.1-point reduction for the comparator. The acquisition reinforces AbbVie's aggressive M&A strategy aimed at securing long-term growth, particularly in its neuroscience division, which has already seen sales grow 20.3% to approximately $5 billion in the first half of 2025. However, this aggressive pipeline-building is not without significant risk, as highlighted by the recent November 2024 failure of two Phase II studies for emraclidine, a key asset from its acquisition of Cerevel Therapeutics. This context frames the bretisilocin deal as a high-conviction bet on a novel therapeutic class to bolster a critical growth franchise, balancing promising early results against the inherent volatility of early-stage drug development.

Key Decisions for Investors

• Investors should view this acquisition as a long-term positive that strengthens AbbVie's pipeline in the high-growth neuroscience area, but must factor in the substantial clinical and regulatory risks inherent to a Phase II psychedelic asset.
• Monitor future clinical trial data for bretisilocin closely, as the $1.2 billion deal value is largely dependent on hitting development and regulatory milestones, which remains a high-risk proposition.
• The recent failure of the Cerevel-acquired drug, emraclidine, serves as a crucial reminder of the binary nature of biotech investments; this new deal reaffirms AbbVie's strategy but also its exposure to early-stage pipeline risk.